Skip to main content

Table 6 Change in CV risk factors from baseline to last treatment (treated set)

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

Mean (SEM)

Linagliptin (n = 5758)

Active comparators (n = 918)

Placebo (n = 2618)

Total comparators (n = 3536)

Total cholesterol, mg/dL

    

Baseline

187 (0.6)

186 (1.3)

187 (0.9)

187 (0.8)

Change from baseline

1 (0.5)

2 (1.1)

2 (0.7)

2 (0.6)

LDL, mg/dL

    

Baseline

107 (0.5)

104 (1.1)

107 (0.7)

106 (0.6)

Change from baseline

1 (0.4)

4 (0.9)

1 (0.6)

1 (0.5)

HDL, mg/dL

    

Baseline

47 (0.2)

48 (0.4)

47 (0.3)

47 (0.2)

Change from baseline

1 (0.1)

−1 (0.2)

1 (0.2)

1 (0.1)

Triglyceride, mg/dL

    

Baseline

173 (1.8)

180 (4.1)

174 (2.9)

176 (2.4)

Change from baseline

−7 (1.5)

−8 (4.2)

−3 (2.6)

−5 (2.2)

HbA1c, %

    

Baseline

8.1 (0.01)

7.8 (0.03)

8.3 (0.02)

8.1 (0.02)

Change from baseline

−0.7 (0.01)

−0.5 (0.03)

−0.3 (0.02)*

−0.3 (0.02)

Weight

    

Baseline

79.5 (0.25)

83.8 (0.58)

81.1 (0.39)

81.9 (0.32)

Change from baseline

−0.1 (0.05)

1.3 (0.15)

0.1 (0.07)

0.4 (0.06)

Systolic BP (mmHg)

    

Baseline

131 (0.2)

134 (0.5)

132 (0.3)

132 (0.3)

Change from baseline

−1 (0.2)

−1 (0.5)

−1 (0.3)

−1 (0.3)

Diastolic BP (mmHg)

    

Baseline

78 (0.1)

80 (0.3)

78 (0.2)

79 (0.2)

Change from baseline

−1 (0.1)

−1 (0.3)

−1 (0.2)

−1 (0.2)

Heart rate, bpm

    

Baseline

74 (0.1)

73 (0.4)

74 (0.2)

74 (0.2)

Change from baseline

1 (0.1)

−1 (0.3)

1 (0.3)

1 (0.2)

  1. BP, blood pressure; bpm, beats per minute; CV, cardiovascular; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
  2. *Analysis includes data obtained after initiation of glycemic rescue.